Occurrence of hypertension during third‐line anlotinib is associated with progression‐free survival in patients with squamous cell lung cancer (SCC): A post hoc analysis of the ALTER0303 trial

BACKGROUND: There is a lack of targeted therapeutic options for squamous cell lung cancer (SCC). Accelerated hypertension is an issue with many targeted therapies for lung cancer. This study aimed to analyze the efficacy of anlotinib, based on progression‐free survival (PFS) and overall survival (OS...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Jianhua, Chen, Guimin, Wang, Haitao, Wang, Xiuxiu, Han, Baohui, Li, Kai, Wang, Qiming, Zhang, Li, Wang, Zhehai, Cheng, Ying, He, Jianxing, Shi, Yuankai, Chen, Weiqiang, Luo, Yi, Wu, Lin, Wang, Xiuwen, Nan, Kejun, Jin, Faguang, Dong, Jian, Li, Baolan, Liu, Zhian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410552/
https://www.ncbi.nlm.nih.gov/pubmed/34273139
http://dx.doi.org/10.1111/1759-7714.14076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410552/
https://www.ncbi.nlm.nih.gov/pubmed/34273139
http://dx.doi.org/10.1111/1759-7714.14076

Ejemplares similares